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ABSTRACT 
Objective: Hepatitis C virus (HCV) has emerged as a leading cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. According to 
World Health Organization (WHO) there are 180 million people affected with HCV worldwide and about 12.5 million carriers in India. Genotypes of 
HCV can vary in pathogenecity and can impact on treatment outcome. Hence this study was undertaken to know the seroprevalence and different 
genotypes of HCV among hospital based general population in Vijaypur, Karnataka. 
Methods: Study subjects were those attending various Out-Patient Department (OPD) and In-Patient Department (IPD) of Shri B. M. Patil Medical 
College, Hospital and Research Centre, Vijaypur, Karnataka. 5 ml of blood sample was aseptically collected in plain vial from the study subjects. 
Serum was separated and aliquoted in different vials. All the 1,200 serum samples were tested for HCV antibodies by third generation Enzyme 
Linked Immunosorbent Assay (ELISA). The serum samples positive by ELISA were tested for HCV RNA by Reverse Transcription Polymerase Chain 
Reaction (RT-PCR). Serum samples positive for HCV RNA were subjected to geno typing by RFLP (Restriction Fragment Length Polymorphism) and 
direct sequencing. 
Results: Of the 1,200 samples tested, 32 (2.6%) were positive for anti-HCV antibody and 25 (2.1%) were positive for HCV RNA. HCV genotype 1 
(68%) was found to be the most predominant type followed by genotype 3 (32%). The subtypes of genotype 1 were 1a and 1b, whereas subtypes of 
genotype 3 were 3a and 3b. 
Conclusion: The seroprevalence of HCV in this study was 2.6% and HCV genotype 1 and genotype 3 were found to be the predominant genotypes 
respectively. For physicians, knowing the genotype of hepatitis C virus is helpful in deciding type and duration of therapy. In addition, knowledge of 
circulating genotypes could impact on future vaccine formulations. 
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INTRODUCTION 
Hepatitis C virus (HCV), since its discovery in 1989, has been 
considered a leading cause of chronic hepatitis which can progress to 
liver cirrhosis and hepatocellular carcinoma [1]. According to World 
Health Organization (WHO), there are 180 million people infected with 
HCV worldwide [2] and about 12.5 million carriers in India [3]. 
HCV is an enveloped positive strand ribonucleic acid (RNA) virus 
belonging to genus hepaci virus in the family flaviviridae [4]. The 
RNA genome comprises of about 9500 nucleotides with a single 
open reading frame that encodes a polypeptide precursor of 3000 
amino acids and is flanked by the non coding regions at both the 5’ 
and the 3’ termini [5]. 
The poly protein precursor is cotranslationally processed by host 
signal peptides to yield the structural (core [c] and envelope [E1 and 
E2]) and the non-structural proteins (NS1, NS2, NS3, NS4A, NS4B, 
NS5A and NS5B) [6]. 
HCV has been classified into six major genotypes and into more than 
90 subtypes distributed across the world [7]. The HCV genotypes too 
have distinct geographical distribution and may have a bearing on 
the duration of treatment and outcome, [8] although the impact of 
HCV genotype in progression of the disease is still controversial [7]. 
Studies in India have revealed a seroprevalence of 1.8% of HCV 
infection among general population [9]. 
The conventional antiviral therapy against HCV is either mono 
therapy with interferon (IFN) or in combination with ribavirin [7]. 
The response to therapy differs across genotypes, while up to 80% 
of the genotypes 2 and 3 can be cured with standard of care 
treatment consisting of pegylated or standard IFN-α and ribavirin, 
[10]. geno types 1, 4, 5 and 6 have been reported to show poorer 
response. In the present study, we estimated the seroprevalence and 
analyzed the genotypes of HCV among hospital based general 
population in Vijaypur. Our study will help in knowing the 
seroprevalence and genotypes of HCV prevalent in this region, which 
in turn helps to choose appropriate treatment for HCV infection. 
MATERIALS AND METHODS 
The study was conducted in Department of Microbiology, Shri B. M. 
Patil Medical College (SBMPMC), H & RC, Vijaypur, Karnataka. All 
patients attending Out-Patient Department (OPD) and In-Patient 
Department (IPD) of SBMPMC, H & RC from April 2011 to July 2014 
were included in the study. A detailed medical history including risk 
factors was taken. The study protocol was approved by an 
Institutional Ethics Committee of BLDE University, Vijaypur. 
Informed consent was taken from all the patients. Proforma was 
maintained for each patient containing clinical information about 
his/her previous exposure to risk factors. 
5 ml of blood sample was aseptically collected in plain vial from the 
study subjects. Serum was separated and aliquoted in different vials 
and stored at-70 °C until tested. Repeated freezing and thawing were 
avoided. The following tests were performed on serum samples:  
Serological studies 
Anti-HCV antibodies-using commercially available third generation 
ELISA Kits which comprised of Core, E1, E2, NS3, NS4 and NS5 
antigens of HCV (SD HCV ELISA, Bio Standard Diagnostics Pvt Ltd, 
India), as per manufacturer instructions. Anti-HCV antibodies positive 
samples were further processed for the next step evaluation. 
Viral RNA extraction 
HCV viral RNA was extracted from the serum samples positive for 
HCV antibodies using Qiagen (Germany) RNA according to 
manufacturers’ instructions. HCV RNA was extracted from serum 
and eluted in 50 µl of elution buffer. Eluted RNA was stored at-70 °C 
until further processed. 
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Detection of HCV RNA by RT-PCR 
RT-PCR was carried out by the modified method of Mellor et al. The 
RNA was denatured by heating at 70 °C for 3 min prior to RT-PCR, and 
reverse transcribed at 42 °C for 60 min, in a PCR tube containing 1X RT 
buffer, 10 mM deoxyribonucleoside triphosphates, 20 U RNase 
inhibitor, 50 U murine leukemia virus reverse transcriptase, 20 pmol 
primer (core region P1: 5 × ATGTACCCCATGAG/TA/GTCGGC 3 × anti-
sense) to a final volume of 20 µl. The c-DNA product was denatured at 
95 °C for 5 min, then cooled at 4 °C for 5 min and used for direct PCR. 
Direct polymerase chain reaction  
Direct PCR was performed in the reaction mixture containing PCR 
buffer (10×), 2 mM MgCl2, 10 mM deoxynucleotide triphosphates 
(dNTPs), 20 pmoles primers (sense P2: 5′ACTGCCTGATAGGGTGC 
TTGCG AG 3′) and anti-sense (P1: 5′ ATGTACCCCATGAG/TA/GTCGGC 
3′) for 5 × NCR core region, 0.75 U Taq Deoxyribonucleic Acid (DNA) 
polymerase, in a total reaction volume of 25 µl. 
Nested-PCR was performed in a reaction mixture containing PCR 
buffer (10×) 2 mM MgCl2, 10 mM dNTPs, 20 pmoles primers (sense 
P3: 5′ ACTGCCTGATAGGGTGCTTG CGAG3′) and anti -sense (P4: 5’ 
ATGTACCCCATGAG/TA/GTCGGC 3 ′) for 5 × NCR core region, 0.75 U 
Taq DNA polymerase, in a total reaction volume of 25 µl. 
Amplified PCR product was electro phoresed in ethidium bromide 
stained 2% nu sieve agarose gel with commercially available 100 bp 
DNA marker (Fermentas). Specific bands of HCV were visualized 
under ultraviolet light of Wealtec gel doc system. Positive and 
negative controls were also included. 
HCV RNA quantification 
Quantitative HCV RT-PCR was performed using the light cycler 
taqman master mix kit (Roche Diagnostics GmbH, Mannheim, 
Germany) on Roche Light cycler as per manufacturer’s instructions.  
The unit of the HCV RNA quantification was copies/ml. The range of 
standard used in quantitative analysis was 102-108
The restriction fragment length polymorphism (RFLP) analysis was 
carried out using the nested PCR product of RNA positive samples 
(20-30 µl). The amplified nested PCR product was digested with 
three enzymes Accl, Mbol and BstN1 and incubated at 37 °C for 
overnight in a specific endonuclease buffer. The digested product 
was loaded onto 3% nu sieve agarose gel and the restriction pattern 
was analyzed using Wealtec gel doc System (fig. 1 and 2). The RFLP 
was followed by direct sequencing for determination of HCV 
genotype. The nested PCR product and the sense primer were used 
for sequencing reaction. 
copies/ml. 
HCV genotyping  
 
 
Fig. 1: The RFLP pattern of HCV genotype. Lane 1: 100 bp marker, 
Lane 2 and 4: genotype 1b (234 bp), Lane 5: Negative control, Lane 
7: genotype 3b (176 bp), Lane 8 and 10: genotype 3a (232 bp) 
 
 
Fig. 2: The RFLP Pattern of HCV genotype. Lane 1: 100 bp DNA 
marker, Lane 2: Negative control, Lane 3: genotype 1a (209 bp) 
 
RESULTS 
A total of 1,200 patients were recruited in the study. Majority of 
these patients belonged to Vijaypur city and the neighboring small 
towns and villages. Of the 1,200 patients screened, 32 (2.6%) were 
found positive for ant-HCV antibody. Age and sex distribution of 
hospital based general population with HCV seropositivity is shown 
in table 1 below: 
  
Table 1: Age and sex distribution of hospital based general population with HCV seropositivity 
Age 
Group (In years) 
Males Males anti-HCV 
positive (In %) 
Females Females anti-HCV 
positive (In %) 
Total anti-HCV 
Positive (In %) 
0-9 105 1(0.95%) 91 1(1.1%) 2(1.02%) 
10-19 97 2(2.1%) 99 1(1.0%) 3(1.53%) 
20-29 110 3(2.7%) 92 2(2.2%) 5(2.48%) 
30-39 108 3(2.8%) 96 5(5.2%) 8(3.92%) 
40-49 116 7(6.0%) 90 3(3.3%) 10(4.63%) 
≥50 110 2(1.8%) 86 2(2.3%) 4(2.04%) 
Total 646 18(2.8%) 554 14(2.5%) 32(2.6%) 
 
25 (2.1%) out of 32 were found to have active infection (HCV RNA 
positive). 25 HCV RNA positive samples were subjected to genotype 
determination using RFLP followed by direct sequencing. Genotype 
1 was the commonest type observed in 17 (68%) patients followed 
by genotype 3 in 8 (32%) patients. Among genotype 1, subtypes 1a 
and 1b were most commonly isolated. In genotype 3 subtypes 3a 
and 3b were most frequently isolated. 
Genotypes 1a and 1b were observed in 10 (58.8%) and 7 (41.2%) 
patients respectively whereas types 3a and 3b were seen in 3 
(37.5%) and 5 (62.5%) patients respectively. Out of 25 PCR positive 
patients, 15 (60%) were males and 10 (40%) were females. 
Distribution pattern of HCV genotypes according to the gender is 
given below in table 2. 
 
Table 2: Distribution pattern of HCV genotypes according to age 
Gender Genotype Genotype Genotype Genotype 
1a 1b 3a 3b 
Male (N=15) (60%) 6 (40%) 4 (26.7%) 2 (13.3%) 3 (20%) 
Female (N=10) (40%) 4 (40%) 3 (30%) 1 (10%) 2 (20%) 
Total (N=25) (100%) 10 (40%) 7 (28%) 3 (12%) 5 (20%) 
N=Number, Distribution pattern of HCV genotypes according to the age is given below in table 3 
Salmani et al. 
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Table 3: Distribution pattern of HCV genotypes according to age 
Age Genotype Genotype Genotype Genotype 
1a 1b 3a 3b 
˂ 18 (N=4) (16%) 2 (50%) 2 (50%) 0 (0%) 0 (0%) 
18-40(N=9) (36%) 4 (44.4%) 2 (22.2%) 0 (0%) 3 (33.3%) 
41-60(N=12) (48%) 4 (33.3%) 3 (25.0%) 3 (25.0%) 2 (16.7%) 
Total (N=25) (100%) 10 (40.0%) 7 (28.0%) 3 (12.0%)) 5 (20.0%) 
N=Number 
 
Viral load quantification was carried out in HCV RNA positive 
patients. The average viral load of patients infected with genotype 1 
was significantly higher than those infected with genotype 3. 
DISCUSSION  
Currently India harbors an estimated 10-15 million chronic carriers 
of HCV, which is a major cause of liver related mortality and 
morbidity. Overall a seropositivity of 2.6% was observed among 
hospital based general population in this study. This is similar to 
other hospitals based study done in 2002 by S Mishra et al. [11] in 
contrast to the study done by S Bhattacharya et al. (which showed a 
seroprevalence of 4.8%) [12]. The prevalence seems to increase 
with age because of the continuing risk of exposure The prevalence 
of HCV in the 0-9 y’s age group could be due to the enhanced risk of 
exposure from perinatal transmission of the virus. In conformity 
with other studies, a higher prevalence was found among males 
(2.8%) than among females (2.5%). 
Knowledge of genotype is crucial for management of HCV infection 
and prediction of prognosis. [13]. HCV genotypes show differing 
distributions in different geographic regions. In the United States, 
about 70% of cases are caused by genotype1, 20% by genotype2 and 
about 1% by each of the other genotypes [14]. Genotype 1 is also the 
most common in South America and Europe [15]. In India, genotype 
3 has been predominant in the Northern, Eastern as well as Western 
region [16] while in South India, genotypes 1 and 3 have been 
reported in decreasing order of frequency [17]. Genotype 3 has also 
been reported to be the commonest type from the neighboring 
countries of Nepal and Pakistan, while in the eastern countries of 
Thailand, Vietnam and Japan, genotype 1 is the most prevalent [18]. 
The most common genotypes isolated in our study were 1 and 3 
respectively. Our finding correlates well with the study conducted 
by Raghuraman S et al. in 2004. Knowledge of regional distribution 
of HCV genotypes is important since this could influence the 
configuration of diagnostic assays as well as vaccine designs. [17]. 
within genotype 1, we observed that subtype 1a (58.8%), the 
current most prevalent sub type. 
According to our study, in the group of patients of age less than 18 y 
50% of patients were found to be infected with HCV genotype 1a 
and also 50% 0f patients with 1b. In the age group 18-40 y, 44.4% 
had 1a genotype infection, 22.2% showed 1b genotype infection 
while 33.3% showed 3b genotype infection of HCV. The patients of 
age group 41-60 y showed the percentage to be 33.3% of 1a, 25% of 
1b, 25% of 3a and 16.7% 0f 3b. Genotypes 3a and 3b were not found 
in age group of less than 18 y and 3a genotype was not found in age 
group 18-40 y. 
Our study showed no significant difference in genotype distribution 
in relation to gender. Various genotypes were equally distributed in 
relation to gender. 
HCV plasma viral load, also called HCV viremia, is expressed in 
copies per milliliter. In our study, we used PCR to quantify HCV 
viremia. In our study, mean HCV RNA were higher in patients 
infected with HCV type 1 than in patients infected with HCV type 3. 
Our result correlated well with a study conducted [19]. 
For physicians, knowing the genotype of hepatitis C is helpful in 
deciding type and duration of therapy [20]. Several clinical trials of 
pegylated interferon/ribavirin therapy have revealed significant 
differences in response rates for the various HCV genotypes. 
Individuals with genotypes 2 and 3 are more likely than individuals 
with genotype 1 to respond to therapy with alpha interferon or the 
combination of alpha interferon and ribavirin [21]. 
One probable reason for more treatment failures with HCV genotype 1 
could be its efficient replication ability enabling it to establish higher 
viral RNA compared to other genotypes. [22]. In the present study, 
patients with HCV genotype 1 had significantly higher viral load as 
compared to genotype 2 and 3. Patients with high viral load present a 
poor response to interferon therapy than those with lower levels. The 
probability of a relapse after cessation of therapy is higher in patients 
with high HCV RNA copy numbers prior to therapy [23]. 
CONCLUSION 
There is a scarcity of information on HCV prevalence particularly in 
developing counties like India. Our study on the prevalence of HCV 
infection among hospital based general population is sure to provide a 
useful insight to researchers working on HCV infection. There is an 
association between different types of genotypes and viral load. 
Further studies should be carried out to determine the association of 
viral load with different genotypes. The information provided by the 
present study provides valuable information to physicians in clinical 
decision making. For physicians, knowing the genotype of hepatitis C 
is helpful in deciding type and duration of therapy. A continued 
monitoring of HCV genotypes is essential for the optimum 
management of chronically infected patients. In addition, knowledge 
of circulating genotypes could impact on future vaccine formulations. 
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